Background: Acute myeloid leukemia (AML) is a heterogeneous disorder characterized by clonal expansion of myeloid progenitors in the bone marrow and peripheral blood Objectives: This study aimed to assess the role of FLT3 (ITD) gene mutation in AML patients and to find out the impact of the CD34 expression in these cases. Subjects : 30 subjects of adult patients with newly diagnosed AML were included in this study. Results: Patients were classified into favorable (6.6%), intermediate (80%) and unfavorable (13.3%) according to cytogenetic abnormalities. Mean value of CD34% (± SD) among cases was 45.53±25.32 with median 35.85 and range (5-91), While it was 42.52±29.9 with median 30.85 and range (5-91) among FLT3-ITD positive cases and 44.21±22.67 with median 39.3and range (16-88) among FLT3-ITD negative cases with no significant statistical relation between FLT3-ITD gene and CD34, P (0.672). CD34 positivity among FLT3-ITD positive cases showed 9 cases (75%) CD34% positive and 3 cases (25%) CD34% negative while among FLT3-ITD negative cases there were 15 cases (83.3%) CD34% positive and 3 cases (16.7%) CD34% negative, with no significant statistical relation. As regard the outcome, among FLT3-ITD positive cases 5 cases (41.7%) underwent relapse and 7 cases (58.3%) died. On the other hand among FLT3-ITD negative cases one case (5.6%) underwent relapse and 11 cases (61.1%) died, There is significant elevation in the relapsed cases among the FLT3-ITD positive cases (P = 0.025), while there is no significant relation between FLT3-ITD gene and death with (P = 0.879).